Postmarketing experience with topiramate and cognition. - Wikidata - awgldk - TriplyDB

Postmarketing experience with topiramate and cognition.

Postmarketing experience with topiramate and cognition.

http://www.wikidata.org/entity/Q42660595

about

The effects of antiepileptic drugs on cognitive functional magnetic resonance imaging Effects of topiramate on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition in recently abstinent methamphetamine-dependent individuals.Behaviour, cognition and epilepsy.Efficacy and tolerability of the new antiepileptic drugs, II: Treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society.Cognitive Effects of Low-dose Topiramate Compared with Oxcarbazepine in Epilepsy Patients Review of topiramate for the treatment of epilepsy in elderly patients.Zonisamide discontinuation due to psychiatric and cognitive adverse events: a case-control study Clinical experience with open-label topiramate use in infants younger than 2 years of age.The cognitive impact of antiepileptic drugs.Cognitive effects of atypical antipsychotics: focus on bipolar spectrum disorders.Comparative Long-Term Effectiveness of a Monotherapy with Five Antiepileptic Drugs for Focal Epilepsy in Adult Patients: A Prospective Cohort Study Safety and tolerability of emerging pharmacological treatments for bipolar disorder.Determinants of outcome in childhood epilepsy.Topiramate and its clinical applications in epilepsy.Topiramate in the treatment of partial and generalized epilepsy.Psychopharmacology of topiramate: from epilepsy to bipolar disorder.Efficacy and Safety of Topiramate for Essential Tremor: A Meta-Analysis of Randomized Controlled Trials The effect of topiramate plasma concentration on linguistic behavior, verbal recall and working memory Pharmacokinetic-Pharmacodynamic Modeling of Intravenous and Oral Topiramate and Its Effect on the Symbol-Digit Modalities Test in Adult Healthy Volunteers.Combination phentermine/topiramate for obesity treatment in primary care: a review.BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment.Attention-deficit/hyperactivity disorder symptoms in adults with self-reported epilepsy: Results from a national epidemiologic survey of epilepsy.Antiepileptic drugs in migraine and epilepsy: Who is at increased risk of adverse events?Postmarketing Results: Useful, But Proceed with Caution Efficacy and Tolerability of Second and Third Generation Anti-epileptic Drugs in Refractory Epilepsy: A Network Meta-Analysis.Clinical Usefulness of Aripiprazole and Lamotrigine in Schizoaffective Presentation of Tuberous Sclerosis.Effectiveness of topiramate in the prevention of childhood headaches.The role of hippocampal sclerosis in topiramate-related depression and cognitive deficits in people with epilepsy.Levetiracetam for mood stabilization and maintenance of seizure control following multiple treatment failures.Language disturbances as a side effect of prophylactic treatment of migraine.The Effect of Antiepileptic Drugs on Cognition: Patient Perceived Cognitive Problems of Topiramate versus Levetiracetam in Clinical Practice.

P2860

Q27005706-60370F62-70AD-4641-8401-B3265B661354 Q30441589-42ACCF3C-1A93-40CC-BB9E-1B65AE27CDFB Q31026691-6627AE5E-D555-43BF-A17F-6CAE64D6EA12 Q33202111-F1DF2DCB-67CD-4AA1-B532-ADFFF7B7DD63 Q33790784-DBF778EE-24D6-435C-98FC-A066E2602195 Q33819386-5DA149B7-2AD7-4EC2-A74D-5BF129437C0E Q34053280-509F3302-7666-4AD6-860C-767BDA69123A Q35132987-85F061AB-5D90-4A2C-A573-2256AA7350BF Q35588407-DF75AF8E-A700-46E5-AEE3-704D27260C0B Q35618437-6660109A-1765-43F2-825B-616965D24EE0 Q35684007-5FC6A7B1-B440-486B-A2B2-7CEC4BBF36D9 Q36199036-086BE4B1-1F94-45A6-BA78-89481B5E466D Q36344184-655AA188-7876-43E3-8DEE-FC9CDA7C8E16 Q36429751-0C1C9650-C772-481D-B041-ED1EF3D1C7E1 Q37129817-5E34AE06-6837-486A-9A55-6EF9BA40CCFB Q37166152-C6AF4EE2-3D31-4E65-9844-5F94AB816109 Q37176201-C212776F-679F-4B93-9A4F-F266FB317386 Q37244159-41521104-5520-41D1-BAB3-B8BF45611C07 Q37666090-B8DFDA5A-F45B-46A3-B807-B7A457406652 Q38200830-C74CB134-8135-438F-B35A-C4DAD2C5D581 Q38826206-ECE0A912-E2FC-4F20-9B87-E56939CF6475 Q39056793-44A2B647-FA1B-4B58-8E5C-9D8127A51994 Q39107282-C3F5D3A6-65A3-4F84-95D0-EF9A6B766008 Q40467788-46FC5A5F-7951-4A8E-9F03-2BEB3F705DAE Q42113049-CC55856F-FAC8-408B-8C81-194F0599E549 Q42371898-75EE959C-8FDF-4CA2-897C-9F7369B7365F Q44187285-D5137F46-7AF7-4F06-B9C6-99CCCC5866FD Q44667891-222C9F3D-E85E-4FDE-92D7-9DFF6F2B94D2 Q46735559-243CABCF-43B1-44AF-90EF-433BF78EE615 Q46816148-82CC1858-24A6-4E2B-927D-BDCC7FD07FE7 Q48598083-1B1FC17B-1713-463B-BC29-FD609234413B

P2860

Postmarketing experience with topiramate and cognition.

http://www.wikidata.org/entity/Q42660595

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

2001年论文

@zh

2001年论文

@zh-cn

name

Postmarketing experience with topiramate and cognition.

@en

Postmarketing experience with topiramate and cognition.

@nl

type

label

Postmarketing experience with topiramate and cognition.

@en

Postmarketing experience with topiramate and cognition.

@nl

prefLabel

Postmarketing experience with topiramate and cognition.

@en

Postmarketing experience with topiramate and cognition.

@nl

P1433

Q42660595-D0588E5E-08A7-4809-8FCD-015A7B9ABA2D

P1476

Q42660595-195D1554-ED3D-4B3C-829A-D841C579B60E

P2093

Q42660595-0FB19058-D8A5-4CEB-A717-3623F2C8F0B1

Q42660595-1E6DEF37-1C66-4FA3-9C52-6393A22BA182

Q42660595-34DA8BA8-3F36-4F8F-AEE3-B3C370985BB1

Q42660595-6362E8AB-09BB-47DD-8BF4-1F95DF0FB08D

Q42660595-71211EFD-CF2D-452D-8824-3691016C1ADE

Q42660595-96AF3DB2-26A6-4E66-A670-6CD0D0B8DE5F

Q42660595-BC69345F-86AA-46AA-8714-6E6D2CEBC86C

Q42660595-CC7321B6-0081-4A9B-B8BF-B332CA2BF83D

Q42660595-DCCADC98-5EFB-4F0A-8240-465FD4C70CFB

P2860

Q42660595-2D37617D-6485-4060-89A4-D6D777E1520F

Q42660595-2D8246F1-4981-473E-BB3B-DF9A419A0370

Q42660595-4EF046FD-D4E4-47A1-9611-60518056DED4

Q42660595-52E2619D-CA6A-4A3F-8887-D2572C5DD6D0

Q42660595-7FB44B74-0919-4A6E-A817-4EE369E699C3

Q42660595-832F9C3E-FD08-4451-B610-077B2492276B

Q42660595-83B968D9-7CA0-4926-A8DE-44B02F56BBC0

Q42660595-8C0011CD-CDCD-42C0-8164-65BE7DF6E04C

Q42660595-950B1787-65EA-4213-9596-0831D8638297

Q42660595-A2DCC50A-B8E0-407A-B90F-6DDA962A90D7

P304

Q42660595-2514971B-27AE-46BC-B10F-FE38F5AC8A6A

P31

Q42660595-E7D3EC4A-9007-4E0E-A925-56A0A7B5EC5D

P356

Q42660595-863EB4BD-1148-47CA-864F-BB4AD027E0FC

P433

Q42660595-74E4D53F-37B9-4CAE-877C-4D3366FA3175

P478

Q42660595-8DEE7C98-1576-4D0A-9356-8CC8970E0C05

P50

Q42660595-729E9938-3F90-4611-9A7C-E7D2D8B74B24

P577

Q42660595-A2D34B34-3ED9-42F8-AE43-21327D7CB2AF

P5875

Q42660595-A79043AF-9256-41D8-8C44-959A74CD4728

P698

Q42660595-16A274E6-5061-41B9-B575-C3818A67C1F9

P356

J.1528-1157.2001.41700.X

P1433

P1476

Postmarketing experience with topiramate and cognition.

@en

P2093

A Fix

http://www.w3.org/2001/XMLSchema#string

A Kanner

http://www.w3.org/2001/XMLSchema#string

E Faught

http://www.w3.org/2001/XMLSchema#string

G L Morris

http://www.w3.org/2001/XMLSchema#string

J Liporace

http://www.w3.org/2001/XMLSchema#string

L Winters

http://www.w3.org/2001/XMLSchema#string

PADS Investigators. Post-marketing antiepileptic drug survey

http://www.w3.org/2001/XMLSchema#string

S L Goff

http://www.w3.org/2001/XMLSchema#string

W O Tatum

http://www.w3.org/2001/XMLSchema#string

P2860

Topiramate: a review of preclinical, pharmacokinetic, and clinical data.

A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group.

A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group.

Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures.

Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs.

Topiramate in clinical practice: first year's postlicensing experience in a specialist epilepsy clinic

Topiramate: a new antiepileptic drug for refractory epilepsy.

Evaluation of case reports of aplastic anemia among patients treated with felbamate.

Safety of topiramate: adverse events and relationships to dosing.

Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults.

P304

1134-1140

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1528-1157.2001.41700.X

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

42

http://www.w3.org/2001/XMLSchema#string

P50

Jacqueline French

P577

2001-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11767419

http://www.w3.org/2001/XMLSchema#string

P698

11580760

http://www.w3.org/2001/XMLSchema#string